Last reviewed · How we verify
Camrelizumab plus TP
Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor immunity, combined with TP (paclitaxel and cisplatin) chemotherapy.
Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor immunity, combined with TP (paclitaxel and cisplatin) chemotherapy. Used for Esophageal squamous cell carcinoma (Phase 3 trial), Advanced or metastatic solid tumors (investigational).
At a glance
| Generic name | Camrelizumab plus TP |
|---|---|
| Also known as | SHR-1210 plus Docetaxel, Cisplatin |
| Sponsor | Hospital of Stomatology, Wuhan University |
| Drug class | PD-1 inhibitor (combination with chemotherapy) |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Camrelizumab binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with PD-L1/PD-L2 ligands on tumor cells and restoring anti-tumor immune responses. The combination with TP chemotherapy (taxane and platinum-based regimen) provides dual mechanisms: direct cytotoxic tumor killing plus enhanced immunological attack through checkpoint inhibition and chemotherapy-induced immunogenic cell death.
Approved indications
- Esophageal squamous cell carcinoma (Phase 3 trial)
- Advanced or metastatic solid tumors (investigational)
Common side effects
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Chemotherapy-related myelosuppression
- Fatigue
- Nausea and vomiting
- Peripheral neuropathy
Key clinical trials
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy (PHASE2)
- PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer (PHASE3)
- Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy (PHASE2)
- Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma (PHASE3)
- Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy (PHASE3)
- A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Camrelizumab plus TP CI brief — competitive landscape report
- Camrelizumab plus TP updates RSS · CI watch RSS
- Hospital of Stomatology, Wuhan University portfolio CI